Welcome, you are not signed in yet.
Log in? New User, Register?
Registration is FREE and offers great benefits
Today is: Tue, Sep 7, 2010 | 20:12 EDT
Add our site to your favorites
Your default homepage
Home
>>
Tech Directory
>>
Gemin X Pharmaceuticals, Inc.
Business Description
Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in Phase 1 clinical trials in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec. www.geminx.com
Tech Directory
Gemin X Pharmaceuticals, Inc.
| Last Update 2008/1/30 12:25 |
Category
Life Sciences
Biotechnology
Tel Number 514 281-8989
Fax Number 514 281-8540
Biotechnology
| Headoffice | |
| 3576 avenue du Parc, Suite 4310, Montréal, QC H2X 2H7 |
Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in Phase 1 clinical trials in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec. www.geminx.com
Executives and Directors
Management
Gordon C. Shore, Ph.D. | Interim CEO, Chief Scientific Officer and Co-founder
Michael Dixon, C.A. | Chief Financial Officer
Jean Viallet, M.D. | Chief Medical Officer
Pierre Beauparlant, Ph.D. | Vice President, Biology and Scientific Development
Mark S. Berger, M.D. | Vice President, Clinical Development
Jeffrey R. Hincks, Ph.D. | Vice President, Drug Development
Mark Mariani, M.Sc. | Senior Director, Regulatory Affairs and Compliance
Directors
Robert G. McNeil, Ph.D.
Gordon C. Shore, Ph.D.
Timothy J. Barberich
Aaron Davidson, MBA
Robert Gorman, Ph.D.
Andrew R. Jordan, CPA
Eric W. Roberts
Management
Gordon C. Shore, Ph.D. | Interim CEO, Chief Scientific Officer and Co-founder
Michael Dixon, C.A. | Chief Financial Officer
Jean Viallet, M.D. | Chief Medical Officer
Pierre Beauparlant, Ph.D. | Vice President, Biology and Scientific Development
Mark S. Berger, M.D. | Vice President, Clinical Development
Jeffrey R. Hincks, Ph.D. | Vice President, Drug Development
Mark Mariani, M.Sc. | Senior Director, Regulatory Affairs and Compliance
Directors
Robert G. McNeil, Ph.D.
Gordon C. Shore, Ph.D.
Timothy J. Barberich
Aaron Davidson, MBA
Robert Gorman, Ph.D.
Andrew R. Jordan, CPA
Eric W. Roberts
Hits: 3
Rating: 0.00 (0 votes)
Print
Tell a Friend
The comments are owned by the poster. We aren't responsible for their content.
| Poster | Thread |
|---|